Upper Respiratory Tract Infection Treatment Market Size, Share, Growth Report 2030

Upper Respiratory Tract Infection Treatment Market

Upper Respiratory Tract Infection Treatment Market - By Distribution Channel (Retail Pharmacies, Online Sales, And Hospital Pharmacies), By Treatment (Drug Treatment (NSAID, Antibiotics, And Others) And By Topical Treatment (Nasal Decongestant, Cough Suppressant, And Others)), And By Region- Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2025

Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-1720 Published Date: Feb-2021 Status : Published

The global Upper Respiratory Tract Infection Treatment market size, which was estimated at about 36.94 (USD Billion) in 2018 and is predicted to accrue earnings worth 58.99 (USD Billion) by 2025

Upper Respiratory Tract Infection Treat Market

Global Upper Respiratory Tract Infection Treatment Market Size

The global Upper Respiratory Tract Infection Treatment market, which was estimated at about 36.94 (USD Billion) in 2018 and is predicted to accrue earnings worth 58.99 (USD Billion) by 2025, is set to record a CAGR of nearly about 6.3% over 2019-2025. The report offers a valuation and analysis of the Upper Respiratory Tract Infection Treatment market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, limitations, sales estimates, avenues, current & emerging trends, and industry-validated market data. The report offers historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on value (USD Billion).

Global Upper Respiratory Tract Infection Treatment Market SizeRequest Free Sample

Upper Respiratory Tract Infection Treatment Market: Overview

Upper respiratory tract infection is an illness that is caused by various viruses & bacteria. Myriad kinds of upper respiratory tract infections include acute bronchitis, flu, laryngitis, common cold, pharyngitis, sinusitis, sore throat, nasal obstruction, tonsillitis, otitis media, and respiratory distress syndrome. Furthermore, symptoms of upper respiratory tract infection include headache, low-grade fever, malaise, sinus pain, running nose, myalgia, breath shortness, nausea, body ache, cough, vomiting, conjunctivitis, sneezing, and diarrhea. Apparently, upper respiratory tract infection can be treated through decongestants, ibuprofen, guaifenesin, prednisone, diphenhydramine, and codeine. Moreover, Decongestants and antihistamine medicine are used in combination for restricting cough, nasal congestion, and various other symptoms in adult population.  

As per NIH researchers, upper respiratory tract infection is defined as upper airway irritation & swelling due to cough without being associated with pneumonia, COPD, chronic bronchitis, and emphysema.

Upper Respiratory Tract Infection Treatment Market: Growth Drivers

The surge in the cases of respiratory ailments, technological breakthroughs in medicine developments, and easy access to generic medicines will steer the expansion of upper respiratory tract infection treatment industry over the years ahead. Apart from inoculation, antiviral chemoprophylaxis can also prevent flue and is also considered as adjunct to inoculation in particular cases. It is also used when there is an unavailability of vaccines or in the condition when inoculation cannot be done.

For instance, antiviral chemoprophylaxis is given to those persons suffering from influenza

(1) who fall in high risk zone for inoculation as a result of contraindication,

(2) those individuals who when vaccinated do not provide an adequate immune response,

(3) for high-risk individuals who are constantly exposed to flue, and

(4) for controlling spread of disease in high-risk individuals across various institutions.

All these aforementioned aspects are projected to create lucrative growth avenues for upper respiratory tract treatment infection market over the years ahead.

Furthermore, antiviral therapy for flu assist in reducing time of flu symptoms, reduces the duration of stay at hospitals, and helps in minimizing the complication risks. This, in turn, will proliferate the growth of upper respiratory tract infection treatment market over the years to come. As per the evidence-based research made by Cochrane, Vitamin C, which is utilized as routine prophylaxis at nearly 0.2 grams doses for treating common cold symptoms, has demonstrated modest & constant effect on common cold in adults as well as children. This will support the expansion of upper respiratory tract infection treatment industry over the years ahead.  

Apparently, the common bacterial agents that cause sinusitis include S. Pneumonia, H. Influenza, S. Aureus, S. Pyogenes, and M. Catarrhalis. Moreover, amoxicillin is an antibacterial drug that is used for treating sinusitis. The other medicine used for treating sinusitis is cephalexin when the disease is chronic or recurs. All these aforementioned factors will contribute immensely towards upper respiratory tract infection treatment market size in the foreseeable future.

North America To Make Lucrative Contributions Towards Overall Market Revenue By 2025

The expansion of upper respiratory tract infection treatment industry in North America over the forecast timespan is attributed to surge in the incidences of upper respiratory tract infections across the U.S. Apart from this, increase in the home visits by physicians due to upper respiratory tract infections and escalating demand for over the counter medicines to treat these infections will steer the expansion of upper respiratory tract infection treatment market in North America over the ensuing years.

To know more about this report, Request a FREE sample copy

Report Scope: 

Report Attributes Report Details
Report Name Upper Respiratory Tract Infection Treatment Market Research Survey Report
Market Size in 2018 USD 36.94 Billion
Market Forecast by 2025 USD 58.99 Billion
Compound Annual Growth Rate CAGR of 6.3%
Number of Pages 110
Forecast Units Value (USD Billion), and Volume (Units)
Key Companies Covered Pfizer Inc, Collegium Pharmaceutical Inc, Merck & Co. Inc, Alcon Inc, Sandoz Inc, GlaxoSmithKline plc, Verona Pharma Plc, Teva Pharmaceuticals, Hospira Inc
Segments Covered By Distribution Channel, By Treatment, Regional Analysis
Regions Covered North America, Europe, Asia Pacific (APAC), Latin America, Middle East and Africa (MEA)
Countries Covered North America: U.S and Canada
Europe: Germany, Italy, Russia, U.K, Spain, France, Rest of Europe
APAC: China, Australia, Japan, India, South Korea, South East Asia, Rest of Asia Pacific
Latin America: Brazil, Argentina, Chile
The Middle East And Africa: South Africa, GCC, Rest of MEA
Base Year 2018
Historical Year 2016 - 2018
Forecast Year 2019-2025
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.

 

Competitive Landscape

The key players profiled in the study and influencing the growth of upper respiratory tract infection treatment industry are Pfizer Inc., Collegium Pharmaceutical, Inc., Merck & Co., Inc., Alcon, Inc., Sandoz, Inc., GlaxoSmithKline plc, Verona Pharma Plc, Teva Pharmaceuticals, and Hospira, Inc.

The global upper respiratory tract infection treatment market is segmented as follows:

By Distribution Channel

  • Retail Pharmacies
  • Online Sales
  • Hospital Pharmacies

By Treatment

  • Topical treatment
    • Cough Suppressant
    • Nasal Decongestant
    • Others
  • Drug treatment
    • NSAID
    • Antibiotics
    • Others

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

FrequentlyAsked Questions

Surge in the cases of respiratory ailments, technological breakthroughs in medicine developments, and easy access to generic medicines will steer the expansion of upper respiratory tract infection treatment industry over the years ahead. Apart from inoculation, antiviral chemoprophylaxis can also prevent flue and is also considered as adjunct to inoculation in particular cases. It is also used when there is unavailability of vaccines or in the condition when inoculation cannot be done. For instance, antiviral chemoprophylaxis is given to those persons suffering from influenza (1) who fall in high risk zone for inoculation as a result of contraindication, (2) those individuals who when vaccinated do not provide adequate immune response, (3) for high-risk individuals who are constantly exposed to flue, and (4) for controlling spread of disease in high-risk individuals across various institutions. All these aforementioned aspects are projected to create lucrative growth avenues for upper respiratory tract treatment infection market over the years ahead.

According to Zion Market Research report, the global Upper Respiratory Tract Infection Treatment market, which was estimated at about 36.94 (USD Billion) in 2018 and is predicted to accrue earnings worth 58.99 (USD Billion) by 2025, is set to record a CAGR of nearly about 6.3% over 2019-2025.

North America is likely to make noteworthy contributions towards overall Upper Respiratory Tract Treatment Infection Market revenue over 2019-2025. The growth of the market in the region over estimated timespan can be ascribed to surge in the incidences of upper respiratory tract infections across the U.S. Apart from this, increase in the home visits by physicians due to upper respiratory tract infections and escalating demand for over the counter medicines to treat these infections will steer the expansion of upper respiratory tract infection treatment market in North America over the ensuing years.

The key players profiled in the report include Pfizer Inc., Collegium Pharmaceutical, Inc., Merck & Co., Inc., Alcon, Inc., Sandoz, Inc., GlaxoSmithKline plc, Verona Pharma Plc, Teva Pharmaceuticals, and Hospira, Inc.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed